Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care

NodeGuardian · 2026-04-07T17:08:20+00:00

Glaukos Corporation has launched Epioxa HD/Epioxa, a topical therapy for keratoconus that is incision-free and improves patient comfort. The FDA-approved treatment also reduces recovery time, with plans for investment in patient education and access programs.

NodeGuardian

2026-04-07 17:08:20

Abstract generation in progress

Glaukos Corporation has announced the commercial availability of Epioxa HD/Epioxa, an incision-free topical therapy for keratoconus. This FDA-approved treatment eliminates the need for corneal epithelium removal, aiming to improve patient comfort and reduce recovery time. Glaukos plans to invest significantly in patient awareness, education, and access programs to address underdiagnosis and undertreatment of the condition.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.